Biotechnology

Antengene to Host its First R&D Days on November 16 and November 18, 2021

* Virtual Event (in English) on November 16 * On Site Event with Live Webcast (in Mandarin) on Nov 18 SHANGHAI and HONG KONG, Oct. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, deve...

2021-10-25 20:00 2476

Happiness Biotech Acquires Majority Ownership in Fujian Shennong

NANPING, China, Oct. 25, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), aChina-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce solutions, and the sales of automobile, today announced that it...

2021-10-25 20:00 2375

GC Group strengthens Sustainable Growth for business and customers with "Together To Net Zero" Roadmap

* Announcement by leading chemicals company in line with its 'Chemistry for Better Living' commitment, providing clear pathway to improving people's quality of life through transformation to low carbon business * Ambitious plan will use Three-Pillar Low Carbon Transition Framework, focusing o...

2021-10-25 19:05 1829

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer

HOUSTON and SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreem...

2021-10-25 17:00 1441

Meet the Next Resolution in Medicine -- Polaris Biology Releases Starion™, the next-generation mass cytometer

SHANGHAI, Oct. 23, 2021 /PRNewswire/ -- Polaris Biology, a leading innovator in single-cell technologies, announced today the largest product launch in company history with the introduction of the Starion™ Mass Cytometry System. Dr. Yuzhang Wu, and...

2021-10-23 15:05 2734

Technological supremacy reigns in Chengdu

CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- Chengdu, capital of Southwest China's Sichuan province, is accelerating its development driven by technological innovation thanks to the Chengdu Science and Technology Bureau. An employee of Qitan Tech ...

2021-10-22 21:14 3134

2021 Bio-enzyme Application Explorer Summit held in Chengdu

The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...

2021-10-22 14:23 1174

Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences  International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...

2021-10-22 09:00 1524

Aero HygenX Partners with Ethiopian Airlines for Deployment of Autonomous UV-C Disinfecting Solution

* With hygiene in sharp focus, industry support for Aero HygenX continues to grow * Chemical-free disinfection via UV-C light offers a safer work environment for staff and is gentler on aircraft interiors * A global problem requires global solutions: It is the intention of Aero HygenX to ...

2021-10-21 21:57 2090

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

SHANGHAI and HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-10-21 16:00 2733

Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray

SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company")    , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...

2021-10-21 15:58 1222

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...

2021-10-21 10:31 2261

Singapore-based Biosyngen receives 500 million yuan in investment

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- At the 12th Singapore-Guangdong Collaboration Council (SGCC) meeting held online onOctober 20, Singapore-based Biosyngen Pte. Ltd. ("Biosyngen") announced its partnership with wholly state-owned Chinese company Science City (Guangzhou) Investment Group Co....

2021-10-21 09:30 4227

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...

2021-10-21 08:05 1689

EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization

CHICAGO and KANSAS CITY, Mo., Oct. 20, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, andIntouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreemen...

2021-10-20 22:34 3060

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...

2021-10-20 21:24 4085

Creatus Biosciences Inc. acquires the exclusive option to IP Assets from Stora Enso to Commercialize Xylitol Bioproduction from Biomass

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- Creatus Biosciences Inc. ("Creatus") have signed a purchase agreement with Virdia, LLC ("Virdia"), a wholly-owned subsidiary of Stora Enso Oyj ("Stora Enso") to commercialize end-to-end production of xylitol by fermentation from biomass. The agreement ...

2021-10-20 21:00 1422

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- HistoIndex , a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis an...

2021-10-20 18:00 1485

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China

* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seeks to accelerate its business development activities with Daewoong, their partner for the development and commercialization of BBT-401 in 22 Asian countries SEONGNAM, South Korea and CHENGDU, China, ...

2021-10-20 07:00 1272

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...

2021-10-20 05:08 1510
1 ... 186187188189190191192 ... 288